Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an announcement.
CSPC Pharmaceutical Group reported a significant decline in its financial performance for the first half of 2025, with total revenue decreasing by 18.5% and profit attributable to shareholders dropping by 15.6% compared to the previous year. The company declared a reduced interim dividend and continued its share buy-back program to enhance shareholder returns. Despite the financial setbacks, CSPC remains committed to its strategic focus on innovation and internationalization, aiming to strengthen its market position and drive sustainable development.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is an innovation-driven pharmaceutical enterprise that integrates research and development, manufacturing, and sales. The company focuses on developing innovative products to address clinical treatment challenges, with a strong emphasis on key therapeutic areas such as oncology, psychiatry, neurology, and cardiovascular diseases. With R&D centers in China and the US, CSPC aims to enhance its domestic and international competitiveness through a dual-engine strategy of innovation and internationalization.
Average Trading Volume: 214,665,843
Technical Sentiment Signal: Buy
Current Market Cap: HK$122.4B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.